Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Stanford University
Information provided by (Responsible Party):
Stanford University Identifier:
First received: September 16, 2011
Last updated: November 17, 2014
Last verified: November 2014

Docetaxel and cetuximab are FDA approved for the treatment of squamous cell carcinoma of the head and neck. Cisplatin and carboplatin, while not FDA approved for Squamous Cell Carcinoma of the Head and Neck (SCCHN), have been used as standard of care in patients with SCCHN in combination with other drugs. This study will determine if weekly cisplatin and docetaxel, in combination with cetuximab, will be effective in palliative treatment of patients with squamous cell carcinoma of the head and neck. These drugs will be given intravenously weekly, repeated 3 of every 4 weeks until evidence of disease progression or unacceptable adverse events.

Condition Intervention Phase
Head and Neck Cancer
Drug: Docetaxel
Drug: Cisplatin
Drug: Cetuximab
Drug: Carboplatin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With SCCHN

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Response rate [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression free survival [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 27
Study Start Date: October 2011
Estimated Study Completion Date: January 2021
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: cisplatin/docetaxel/cetuximab
Patients will be treated weekly with cisplatin, docetaxel, and cetuximab.
Drug: Docetaxel
30 mg/m2 iv
Other Name: Taxotere
Drug: Cisplatin
30 mg/m2 iv
Other Names:
  • cisplatinum
  • Platinol
  • CDDP
  • cis-diamminedichloroplatinum(II)
  • Platinol-AQ
Drug: Cetuximab
C1: 400 mg/m2, thereafter 250 iv
Other Name: Erbitux
Drug: Carboplatin
AUC 2 iv
Other Names:
  • cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
  • Paraplatin
  • Paraplatin-AQ


Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Squamous cell carcinoma of head and neck sites, including all pharynx, larynx, oral cavity, skin and para-nasal sinus sites. Patients with SCC of unknown primary presenting in the neck clinically compatible with head and neck mucosal primary sites are eligible.
  • Patients who have received prior chemoradiation, radiation, and/ or surgery in the potentially curative setting are eligible as long as 3 months has elapsed since the end of the potentially curative treatment ended.
  • Patients must be greater than 16 years old.
  • ECOG Performance Status < 3 at enrollment is required.
  • Laboratory value requirements at enrollment:

    • Absolute neutrophil count > 1500/mm3
    • Platelet count >100K/mm3
    • Hemoglobin > 8 g/dL
    • AST and ALT < 2.5 x ULN unless liver metastases documented. In this latter case, AST and ALT < 5 x ULN required.
    • Total Bilirubin < 1.5 x ULN unless the patient has Gilbert's syndrome, in which case T. Bilirubin < 2.5 x ULN required
    • Serum Creatinine < 1.5 mg/dL OR an estimated creatinine clearance from 24 hour urine collection > 50 ml/min
  • Clinical requirements at enrollment:

    • Peripheral neuropathy < grade 2
    • Hearing loss in best ear < grade 2 per Chang criteria if audiogram performed. *24 Formal audiology is not required in patients with no clinical evidence of hearing loss at baseline.
    • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • No prior palliative chemotherapy
  • Patients with active infections including HIV are not eligible. HIV positive patients on HAART with undetectable blood HIV levels are eligible. Patients with a history or serological evidence of exposure to Hepatitis B without active infection are eligible for this study.
  • Patients with prior grade 3 allergic or infusion reactions to docetaxel, cisplatin or cetuximab are not eligible. A history of well tolerated infusion reactions is NOT an exclusion.
  • Pregnant women and/or nursing patients will be excluded from the study because of potential harm to the fetus or nursing infant.
  • Because the primary endpoint of this study is response rate and not survival, patients with a history of other malignancies treated curatively greater than one year prior to enrollment and without evidence of relapse at the time of enrollment are eligible.
  • Patients with brain metastasis are eligible only if by CNS imaging there is no evidence of CNS progression at least 30 days following definitive CNS treatment (resection or radiation).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01437449

United States, California
University of California Davis Medical Center Recruiting
Davis, California, United States, 95616
Contact: Courtney Eddings    916-734-3604      
Stanford University Cancer Institute Recruiting
Stanford, California, United States, 95305
Contact: Ruth Lira    650-723-1367   
Sub-Investigator: Heather A Wakelee, MD         
Sub-Investigator: Harlan Pinto, MD         
Sub-Investigator: Joel Neal, MD         
Sponsors and Collaborators
Stanford University
Principal Investigator: A. Dimitrios Colevas, MD Stanford University
  More Information

No publications provided

Responsible Party: Stanford University Identifier: NCT01437449     History of Changes
Other Study ID Numbers: ENT0033, SU-08222011-8290, 22329, NCI-2011-03271, 22329
Study First Received: September 16, 2011
Last Updated: November 17, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Stanford University:
Quality of Life

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators processed this record on March 01, 2015